Emerging IO checkpoints in gastrointestinal oncology

Area of Science:

• Oncology
• Immunology
• Gastroenterology

Background:

• Gastrointestinal (GI) cancers present significant therapeutic challenges with poor prognoses.
• Immunotherapy has emerged as a transformative approach in oncology.
• Immune checkpoints play a critical role in regulating anti-tumor immunity within the tumor microenvironment.

Purpose of the Study:

• To review the evolving role of specific immune checkpoints in gastrointestinal oncology.
• To highlight the therapeutic potential of targeting TIGIT, VISTA, GITR, STING, and TIM-3.
• To explore the integration of these novel targets with existing treatment modalities.

Main Methods:

• Literature review of recent advancements in immunotherapy for GI cancers.
• Analysis of the molecular mechanisms and clinical implications of key immune checkpoints.
• Synthesis of data from preclinical and clinical studies.

Main Results:

• TIGIT and GITR modulate T cell and NK cell functions.
• VISTA and STING pathways enhance the host's anti-tumor immune response.
• TIM-3 is implicated in T cell exhaustion, presenting a target to overcome immune suppression.

Conclusions:

• Targeting immune checkpoints like TIGIT, VISTA, GITR, STING, and TIM-3 offers promising therapeutic avenues for GI cancers.
• Combination strategies integrating checkpoint inhibitors with conventional therapies may lead to personalized and effective treatments.
• Further research into these checkpoints is crucial for improving patient survival and outcomes in GI oncology.